echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Improving innovation capabilities has become a general trend in the industry, and pharmaceutical equipment companies will continue to increase investment in research and development in the future

    Improving innovation capabilities has become a general trend in the industry, and pharmaceutical equipment companies will continue to increase investment in research and development in the future

    • Last Update: 2023-02-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit
    Under the background that innovation has become the general trend of the development of the pharmaceutical industry, the R&D investment of pharmaceutical companies is increasing
    year by year.
    According to data, from 2016 to 2021, global pharmaceutical R&D expenditure has risen from US$160 billion to US$212 billion, with a compound annual growth rate of 5.

    It is worth noting that at present, in addition to the pharmaceutical industry, the pharmaceutical equipment field as the upstream of the industrial chain has also ushered in a wave
    of R&D innovation.

    In the future, pharmaceutical equipment companies will continue to increase investment in research and development (Image source: Pharmaceutical Network)
    It is reported that in China, the head pharmaceutical machine companies represented by Chutian Technology and Dongfulong have been continuously increasing investment in research and development, constantly enriching product categories, optimizing product structure, actively deploying new tracks such as biopharmaceuticals and vaccines, and continuously meeting the downstream localization replacement needs while promoting the high-quality development
    of the industry.

    Specifically, according to the annual report data of two representative head pharmaceutical machine companies, Chutian Technology and Dongfulong, in Q1~3 of 2020/2021/2022, the annual R&D expenses of Dongfulong were 156 million yuan/285 million yuan/232 million yuan, respectively, showing an overall upward trend

    The annual R&D expenses of Chutian Technology are 288 million yuan/488 million yuan/375 million yuan, respectively, and the company's R&D investment expenses have accounted for about
    10% of the annual revenue in recent years.
    Among them, in the first half of 2022, Chutian Technology further increased its investment in R&D, which was first manifested in an increase of more than
    650 technical R&D personnel over the same period.
    Among them, the introduction of technical backbone talents is the focus, and has shown obvious results, and the number of technical research and development personnel of Chutian Group has reached nearly 2,000 during the reporting period

    At present, pharmaceutical machinery enterprises have produced obvious effects
    under the background of the introduction of technology research and development talents, talent management innovation, and increased investment in research and development.
    For example, Chutian Technology added 19 new invention patents in the first half of 2022; As of June 30, Chutian Technology and its major domestic subsidiaries have a total of 2,609 valid patents, 20 valid PCT international patents and 203 software copyrights, further highlighting the advantages of technical

    The industry generally believes that continuing to increase technology research and development has become the general trend
    of the development of the pharmaceutical equipment industry.
    In fact, many pharmaceutical companies have revealed that they will increase innovation and research and development in
    the future.
    For example, recently, investors are asking Dongfulong "Will it increase research and development in the main pharmaceutical equipment industry in the future?" When asked, it said that it has been committed to providing high-quality products and solutions closer to the pharmaceutical industry with a global vision and continuous innovation ability, and the company will continue to increase investment in research and development, improve independent innovation capabilities, enhance the company's endogenous growth momentum, drive the company's development with innovation, and improve the company's core competitiveness

    It is worth mentioning that the current pharmaceutical equipment industry has entered the era of digitalization and intelligence, in order to embrace the new trend, upstream pharmaceutical equipment companies are actively exploring and developing
    intelligent, automated, continuous equipment and overall solutions.
    It is reported that the biological or sterile preparation production execution system (MES) invested in the research and development of Chutian Technology aims to enhance production compliance and improve enterprise production efficiency, effectively improve paperless office capabilities and production transparent management level, reduce production costs, enhance enterprise information sharing capabilities and mine the value of
    production data.

    In addition, on December 16, 2022, Chunguang Pharmaceutical held a listing ceremony and officially landed on the Beijing Stock Exchange
    According to its announcement, the IPO of Chunguang Pharmaceutical Packaging plans to raise about 250 million yuan, which will be used for the construction project of intelligent automation equipment production base and supplementary working capital project

    In general, the improvement of innovation ability is laying a more solid foundation
    for pharmaceutical equipment companies to further grasp the rapid growth of pharmaceutical engineering equipment demand market opportunities.
    In the future, while continuing to increase the ability of technological innovation, the manufacturing technology and market expansion ability of pharmaceutical enterprises are expected to continue to improve

    ={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
    js?cdnversion='+~(-new Date()/36e5)];
    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.